Uterine fibroids and risk of hypertensive disorders of pregnancy – results from a racially diverse high-risk cohort

Introduction

Uterine leiomyomas (fibroids) are the most common solid symptomatic neoplasm in women, estimated to occur in up to 70% of women by the time of menopause (Stewart and Borah, 2021). Increasing data support an association between uterine fibroids and development of chronic hypertension over the life course (Brewster et al., 2022, Haan et al., 2018). Since pregnancy may be viewed as a “cardiac stress test”, with the development of preeclampsia in pregnancy linked to the development of cardiovascular disease long-term (Ying et al., 2018), understanding the association between uterine fibroids and hypertensive disorders in pregnancy (HDP) has important implications for both offspring and maternal health. While obstetrical complications resulting from the presence of uterine fibroids, including spontaneous abortion, fetal malpresentation, preterm labor, postpartum hemorrhage, and cesarean section have been well-described (Stout et al., 2010) (Michels et al., 2014) (Coronado et al., 2000), the relationship between uterine fibroids and development of HDP has been conflicting. Prior studies have been limited by primarily western European or Asian cohorts and a lack of measurement of important potential confounders including shared risk factors like body mass index (BMI) and race (Biderman-Madar et al., 2005) (Girault et al., 2018) (Conti et al., 2013) (Harlev et al., 2019). Fibroids are more prevalent and occur at younger ages in black women, who also have a higher rate of maternal morbidity and mortality; given these limitations, The Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research has called on researchers to diversify study populations of fibroid patients (Segars et al., 2014). Therefore, the goals of this study were to use a birth cohort of racially diverse participants with well-phenotyped uterine fibroids to assess the impact of the presence of uterine fibroids on the risk of developing hypertensive disorders of pregnancy.

Materials and Methods

Results

A total of 7,030 participants were included in this analysis. Demographic characteristics for included participants with and without uterine fibroids are summarized in Table 1. In addition, demographic characteristics for participants based on method of uterine fibroid diagnosis (ICD, radiologic review, or both) are included in Supplementary Table 2. A total of 7% of women in the Boston Birth Cohort had a diagnosis of uterine fibroids. Twelve percent of women without uterine fibroids developed HDP, and seventeen percent of women with uterine fibroids developed HDP (p=0.001 in univariate analysis). In multivariate analyses controlled for age at delivery, race, pre-pregnancy BMI, education, parity, and smoking status, the odds of HDP were 39% higher in women with uterine fibroids compared to those without (p=0.03). Furthermore, when restricted only to analysis of Black women (N=4454), the odds of HDP were 50% higher in women with uterine fibroids compared to those without when controlled for the same covariates, and when restricted to Hispanic women (N=2440) the odds of HDP were 54% higher in women with uterine fibroids compared to those without when controlled for age at delivery, pre-pregnancy BMI, education, parity, and smoking status.

Sub-analyses were performed based on method of uterine fibroid diagnosis, given that uterine fibroids are often underdiagnosed and symptomatic uterine fibroids versus incidentally noted uterine fibroids may have different risk profiles. Women with a uterine fibroid diagnosed based on ICD code (n=297) versus asymptomatic incidental ultrasound diagnosis without accompanying ICD diagnosis (n=192) had a significantly greater chance of developing HDP (20 vs 15%, p=0.006); however, even in those with incidentally noted uterine fibroid(s), the odds of HDP were 18% higher in women compared to those without uterine fibroids (p=0.048).

The degree of uterine fibroid burden impacting risk was also analyzed. For the women with ultrasound imaging noting uterine fibroids, the median total number of fibroids was 2 (range 1-6). The mean volume of the total fibroid burden was 3.67cm³ (95% CI 1.78 – 13.7cm³). The mean volume of the largest fibroid was 3.1cm³ (95% CI 1.6 - 9.1cm³). Ten percent of women had at least one submucosal fibroid, 47% had an intramural fibroid, and 43% had a subserosal uterine fibroid. In logistic regression models, neither the impact of the size of the largest fibroid, the total fibroid volume, nor the presence of a submucosal fibroid compared to other location mediated the risk of developing HDP.

Finally, women with pre-existing chronic hypertension were censored from the dataset (N=464 women total, 64 with fibroids and 300 without) and this did not chance the magnitude of the effect of odds of HDP based on fibroid presence (p=0.61).

Discussion

Uterine fibroids are highly prevalent tumors in reproductive-aged women, and they pose a significant health burden that disproportionally effects Black women(Kjerulff et al., 1996). In addition to their debilitating symptoms and impact on quality of life(Stewart and Borah, 2021), uterine fibroids are now increasingly associated with the long-term risk of developing cardiovascular disease(Brewster et al., 2022, Haan et al., 2018, Uimari et al., 2016), though whether that is due to shared risk factors or underlying pathophysiology is largely unknown. Given that uterine fibroids will impact up to 10% of all pregnancies(Zhao et al., 2020), there is a critical need to understand the impact of uterine fibroids on hypertensive disorders in pregnancy, as this can have a significant impact on maternal and offspring long-term health(Alsnes et al., 2017, Boyd et al., 2017, Nahum Sacks et al., 2018).

Prior studies regarding the presence of uterine fibroids and the risk of HDP have been conflicting with some studies reporting an association and others not finding any impact of the presence of uterine fibroid. Some of the largest studies to examine this question have been conducted in Asian countries without inclusion of women of African descent (Chen et al., 2021) (Lee et al., 2020) (Gong et al., 2022) (Pan et al., 2019), while others have focused only on infertile women requiring fertility treatment (Biderman-Madar et al., 2005), or have utilized only ICD diagnosis without imaging (Farland et al., 2019), or imaging only in the second trimester of pregnancy when fibroids may be underreported (Farland et al., 2019, Stout et al., 2010). Furthermore, collection of important shared risk factors including BMI and participant age were not uniformly reported.

Our study found that the presence of uterine fibroids was associated with obstetrical outcomes already well-established to be impacted by fibroids, including pre-term birth and delivery via cesarean section (Table 1), confirming the reliability of our cohort. In addition, we found that traditional risk factor associations with HDP were present in our cohort (increased risk with increasing age and BMI, inverse relationship with parity and smoking status, Table 2). We found that even when controlled for important shared risk factors, including age, BMI, and parity the presence of uterine fibroids was independently associated with a significantly increased risk of developing HDP. This risk was also independent of the size, total volume burden, or location of the uterine fibroids. This may indicate that the systemic angiogenic and vasogenic changes that promote fibroid development, rather than the mass effect of the fibroid itself, play a role in abnormal placentation and HDP disease process.

Importantly, the degree of risk that the presence of uterine fibroid(s) imparts was more pronounced in African American and Hispanic women in analyses controlled for shared risk factors like age and BMI. Furthermore, while women with an ICD diagnosis, indicating clinically symptomatic disease, had a greater risk than women with uterine fibroids noted incidentally on imaging, even women with incidentally noted uterine fibroids had a significantly greater risk of developing HDP than women without uterine fibroids.

The two largest studies to previously examine the relationship between uterine fibroids and HDP in the United States include Stout et al and Farland et al (Farland et al., 2019, Stout et al., 2010). Stout et al utilized second trimester fetal anatomy ultrasounds to examine the impact of uterine fibroids on deliveries from 1990-2007 in a single center in St. Louis, Missouri. The prevalence of uterine fibroids in this population was 3.2% and only approximately 20% of the study population was African American; no data are reported for Hispanic recipients. This study did not demonstrate an increase in preeclampsia for women with uterine fibroids in models adjusting for similar covariates to our study, though the p-value was 0.05. Farland et al examined over 92,000 pregnancies linked to hospital discharge records in the Massachussetts All Payers Claims Database. Uterine fibroids were identified by ICD diagnosis and the prevalence was 4.6%; 3.4% of the study population were Non-Hispanic Black women and 4.6% were Hispanic. In this study, the presence of uterine fibroids was associated with an increased relative risk of 12% for developing HDP. In neither study was sub-analysis for race performed.

Strengths of our study include the use of both ultrasound and ICD diagnoses, as this allowed for exploration of both overtly symptomatic disease and those with clinically ‘insignificant’ or overlooked fibroid disease. While an association with increased risk of uterine fibroids was seen for both groups, the risk was higher for clinically diagnosed uterine fibroids, indicating that potentially associated symptoms including presence of anemia may play a mediating role; this should be investigated in future studies. In addition, the presence of ultrasound imaging results in our study allowed for an assessment of the impact of fibroid burden and location.

The fact that the presence of uterine fibroids was associated with HDP, independent of size or location, is intriguing. There is some evidence that there may be a differential response to hypoxia in uterine fibroids compared to myometrial cells (Miyashita-Ishiwata et al., 2022), which could play a role in the pathogenesis of HDP. In addition, there is data from translational work that indicate that inflammation, alterations in the endometrial structure, and molecular signaling could all be postulated to contribute to a mechanism (Boynton-Jarrett et al., 2005, Humphrey, 2008, Kuwahara et al., 2002).

There are important limitations of this work. First, the use of this birth cohort by definition requires that a live birth occurred, and so this study was not able to assess the impact of the presence of uterine fibroids on previable delivery or intrauterine fetal death. Secondly, it is possible that some participants may have had uterine fibroids present on ultrasound imaging but it was not noted in the radiologic reports. Access to the images from the reports was not available at the time of this analysis. However, if there was an increased incidence of uterine fibroids in the group characterized without fibroids, that would only serve to bias our findings towards the null. In addition, this study population is derived from an urban, high risk catchment hospital with significant racial and ethnic diversity. While this may limit generalizability to low-risk populations, this is precisely the group of women for whom studies regarding the impact of uterine fibroids across the life course are needed.

Given the increased prevalence of HDP based on uterine fibroid status in this high-risk population, particular attention to individualized counseling and potentially appropriate clinical interventions and increased monitoring may be beneficial in individuals with this common uterine pathology, whether they are symptomatic or incidentally noted at the time of ultrasound. Uterine fibroids may in fact be an early warning sign of obstetrical complications with long-term impacts for maternal and child health.